Addex Therapeutics Ltd (SWX:ADXN)

Addex Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	0.17	0.4	1.61	1.42	2.92
Other Revenue	-	0.01	0	0.02	0.24
Revenue	0.17	0.41	1.62	1.44	3.15
Revenue Growth (YoY)	-57.81%	-74.64%	11.92%	-54.18%	-18.71%
Cost of Revenue	-	0.85	1.19	8.23	12.82
Gross Profit	0.17	-0.44	0.43	-6.78	-9.67
Selling, General & Admin	2.32	2.31	2.67	3.76	5.84
Research & Development	0.67	-	-	-	-
Operating Expenses	2.99	2.31	2.67	3.76	5.84
Operating Income	-2.82	-2.76	-2.24	-10.54	-15.51
Interest Expense	-0.02	-0	-0	-0.03	-0.06
Interest & Investment Income	-	0.01	0.06	0.03	0.01
Earnings From Equity Investments	-4.01	-2.18	-	-	-
Currency Exchange Gain (Loss)	-	0.02	-0.32	-0.26	0.21
EBT Excluding Unusual Items	-6.84	-4.91	-2.5	-10.8	-15.35
Pretax Income	-6.84	-4.91	-2.5	-10.8	-15.35
Earnings From Continuing Operations	-6.84	-4.91	-2.5	-10.8	-15.35
Earnings From Discontinued Operations	0.11	11.97	-8.06	-10	-
Net Income	-6.73	7.06	-10.56	-20.8	-15.35
Net Income to Common	-6.73	7.06	-10.56	-20.8	-15.35
Shares Outstanding (Basic)	114	98	74	45	34
Shares Outstanding (Diluted)	114	98	74	45	34
Shares Change (YoY)	16.24%	32.04%	64.45%	32.43%	27.88%
EPS (Basic)	-0.06	0.07	-0.14	-0.46	-0.45
EPS (Diluted)	-0.06	0.07	-0.14	-0.46	-0.45
Free Cash Flow	-	-5.37	-8	-16.44	-14.74
Free Cash Flow Per Share	-	-0.06	-0.11	-0.36	-0.43
Gross Margin	100.00%	-108.35%	26.62%	-	-
Operating Margin	-1627.17%	-671.94%	-138.70%	-729.50%	-491.74%
Profit Margin	-3889.59%	1720.75%	-652.75%	-1439.78%	-486.85%
Free Cash Flow Margin	-	-1310.80%	-494.64%	-1137.59%	-467.34%
EBITDA	-2.81	-2.56	-2.23	-10.53	-15.16
EBITDA Margin	-	-	-137.97%	-	-
D&A For EBITDA	0	0.19	0.01	0.01	0.35
EBIT	-2.82	-2.76	-2.24	-10.54	-15.51
EBIT Margin	-	-	-138.70%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.